-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Cy0pkhpK3Amlowh4VujtkSEvbZ0rZBIeRFDsbCFn/yX/Qj39bVe0Z9h9gMweZPcY IYZGcVMnfUwLD75a/wBcXQ== 0001021408-02-001504.txt : 20020414 0001021408-02-001504.hdr.sgml : 20020414 ACCESSION NUMBER: 0001021408-02-001504 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020207 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC CENTRAL INDEX KEY: 0001003124 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561640186 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48083 FILM NUMBER: 02530077 BUSINESS ADDRESS: STREET 1: 3151 SOUTH 17TH ST CITY: WILMINGTON STATE: NC ZIP: 28412 BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: 3151 SOUTH 17TH ST CITY: WILMINGTON STATE: NC ZIP: 28412 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MCNEILL JOHN A JR CENTRAL INDEX KEY: 0001033408 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: PPD INC STREET 2: 3151 17TH STREET EXTENSION CITY: WILMINGTON STATE: NC ZIP: 28412 BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: PPD INC STREET 2: 3151 17TH STREET EXTENSION CITY: WILMINGTON STATE: NC ZIP: 28412 SC 13G/A 1 dsc13ga.txt SC 13G/A - JOHN A. MCNEILL, JR. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (AMENDMENT NO. 5)* Pharmaceutical Product Development, Inc. ---------------------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 717124101 --------- (CUSIP Number) December 31, 2002 ----------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [_] Rule 13d-1(c) [X] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and or any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 ================================================================================ CUSIP NO. 717124101 ---------- - -------------------------------------------------------------------------------- NAME OF ISSUER Pharmaceutical Product Development, Inc. - -------------------------------------------------------------------------------- TITLE OF CLASS OF SECURITIES Common Stock - -------------------------------------------------------------------------------- NAMES OF REPORTING PERSONS. S.S or I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS 1 John A. McNeill - -------------------------------------------------------------------------------- CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 2 (a) [_] (b) [_] - -------------------------------------------------------------------------------- SEC USE ONLY 3 - -------------------------------------------------------------------------------- CITIZENSHIP OR PLACE OF ORGANIZATION 4 United States - -------------------------------------------------------------------------------- SOLE VOTING POWER 5 NUMBER OF 1,752,358 SHARES ------------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6 OWNED BY 0 ------------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 7 REPORTING 1,752,358 PERSON ------------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 8 0 - -------------------------------------------------------------------------------- AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 1,752,358 - -------------------------------------------------------------------------------- CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 10 Not Applicable [_] - -------------------------------------------------------------------------------- PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 - -------------------------------------------------------------------------------- TYPE OF REPORTING PERSON 12 IN - -------------------------------------------------------------------------------- Page 2 Item 1 Issuer (a) Pharmaceutical Product Development, Inc. (b) 3151 South 17/th/ Street Wilmington, North Carolina 28412 Item 2. Person Filing (a) John A. McNeill, Jr. (b) Pharmaceutical Product Development, Inc. 3151 South 17/th/ Street Wilmington, North Carolina 28412 (c) United States (d) Common Stock (e) 717124101 Item 3. Filing Pursuant to Rules 13d-1(b) or 13(d)-2(b) Not Applicable Item 4. Ownership (a) 1,752,358 includes 32,034 held in trust for Mr. McNeill's three children, all of whom reside with Mr. McNeill; 50,000 shares held in the SM Portfolio LLC 2001, a limited liability company, John A. McNeill, Jr., member/manager; 1,230 held in the McNeill Family Limited Partnership, John A. McNeill, Jr., General Partner. Also includes 36,000 shares issuable pursuant to vested options. (b) 3.4% (c) The Reporting Person retains sole voting and dispositive power of all shares. Item 5. Ownership of Five Percent or Less of Class [X] Item 6. Ownership of More than Five Percent on Behalf of Another Person Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable Item 8. Identification and Classification of Members of the Group Not Applicable Item 9. Notice of Dissolution of Group Item 10. Certification Not Applicable Page 3 After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 7, 2002 - ---------------------- Date John A. McNeill, Jr. /s/ Fredric N. Eshelman Name: Fredric N. Eshelman Title: Attorney in Fact* * Signed pursuant to a power of attorney, dated December 16, 1998, included as an exhibit to Schedule 13G filed with the Securities and Exchange Commission by John A. McNeill, Jr. on February 7, 2002. POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of Dr. Fredric N. Eshelman and Rudy C. Howard signing singly, with full power of substitution, his/her true and lawful attorney-in-fact, to execute and cause to be filed and/or delivered, as required under Section 13(d) of the Securities Exchange Act of 1934 (the "Act") and the regulations thereunder, any number, as appropriate, of original, copies, or electronic filings of the Securities and Exchange Commission Schedule 13G Beneficial Ownership Reports (together with any amendments and joint filing agreements under Rule 13-d-1(f) (1) of the Act, as may be required thereto) to be filed and/or delivered with respect to any equity security (as defined in Rule 13(d)-1(d) under the Act) of Pharmaceutical Product Development, Inc. beneficially owned by the undersigned and which must be reported by the undersigned pursuant to Section 13(d) of the Act and the regulations thereunder, and generally to take such other actions and perform such other things necessary to effectuate the foregoing as fully in all respects as if the undersigned could do if personally present. This Power of Attorney is governed by and shall be construed in accordance with the laws of the State of North Carolina. This Power of Attorney is effective until revoked by the undersigned, which revocation shall be evidenced by an instrument in writing in form required by North Carolina law. This Power of Attorney is executed pursuant to the provisions of the North Carolina General Statutes, Chapter 32A, Article 2, with the intention that this Power of Attorney and the authority of said attorney-in-fact hereunder shall continue in effect notwithstanding any incapacity or mental incompetence which may be incurred by the undersigned subsequent to the execution of this Power of Attorney by the undersigned. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of December, 1998. /s/ John A. McNeill, Jr. -----END PRIVACY-ENHANCED MESSAGE-----